Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma
Johannes Brägelmann1, Marcel A Dammert1, Felix Dietlein2
1Molecular Pathology, Institute of Pathology, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany; Department of Translational Genomics, Medical Faculty, University of Cologne, Weyertal 115b, 50931 Cologne, Germany.
Abstract:
Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found that BRD4-NUT-rearranged NUT midline carcinoma (NMC) cells are specifically killed by CDK9 inhibition (CDK9i) and depend on CDK9 and Cyclin-T1 expression. We show that CDK9i leads to robust induction of apoptosis and of markers of DNA damage response in NMC cells. While both CDK9i and bromodomain inhibition over time result in reduced Myc protein expression, only bromodomain inhibition induces cell differentiation and a p21-induced cell-cycle arrest in these cells. Finally, RNA-seq and ChIP-based analyses reveal a BRD4-NUT-specific CDK9i-induced perturbation of transcriptional elongation. Thus, our data provide a mechanistic basis for the genotype-dependent vulnerability of NMC cells to CDK9i that may be of relevance for the development of targeted therapies for NMC patients.
Insights
BRD4-NUT-rearranged NUT midline carcinoma (NMC) cells exhibit a specific vulnerability to cyclin-dependent kinase 9 inhibition (CDK9i). This targeted therapy induces apoptosis and DNA damage response, offering a potential new treatment avenue for NMC patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Kinase inhibitors are crucial for targeted cancer therapy, but druggable oncogenic drivers remain limited.
- BRD4-NUT fusion proteins drive specific cancers like NUT midline carcinoma (NMC).
Purpose of the Study:
- To identify specific vulnerabilities in BRD4-NUT-rearranged NMC cells.
- To investigate the mechanistic basis of targeted therapy response in NMC.
Main Methods:
- Screening of 1,505 kinase inhibitors against NMC cells.
- Analysis of cell death, DNA damage markers, protein expression (Myc), and cell cycle.
- RNA sequencing and ChIP analyses to study transcriptional changes.
Main Results:
- CDK9 inhibition (CDK9i) specifically kills NMC cells dependent on CDK9 and Cyclin-T1.
- CDK9i induces apoptosis and DNA damage response.
- CDK9i perturbs transcriptional elongation in a BRD4-NUT-specific manner, distinct from bromodomain inhibition effects.
Conclusions:
- NMC cells show a genotype-dependent vulnerability to CDK9i.
- CDK9i offers a promising, mechanistically understood therapeutic strategy for NMC.
- Understanding this vulnerability may guide the development of novel targeted therapies for NMC.
Related Concept Videos
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Positive Regulator Molecules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...


